SG11201606619UA - Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders - Google Patents

Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Info

Publication number
SG11201606619UA
SG11201606619UA SG11201606619UA SG11201606619UA SG11201606619UA SG 11201606619U A SG11201606619U A SG 11201606619UA SG 11201606619U A SG11201606619U A SG 11201606619UA SG 11201606619U A SG11201606619U A SG 11201606619UA SG 11201606619U A SG11201606619U A SG 11201606619UA
Authority
SG
Singapore
Prior art keywords
dyslipidemia
obesity
diabetes
treatment
related disorders
Prior art date
Application number
SG11201606619UA
Other languages
English (en)
Inventor
Lothar Schwink
Christian Buning
Heiner Glombik
Matthias Gossel
Dieter Kadereit
Nis Halland
Matthias Lohmann
Christoph Pöverlein
Kurt Ritter
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201606619UA publication Critical patent/SG11201606619UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201606619UA 2014-04-04 2015-04-02 Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SG11201606619UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305491 2014-04-04
PCT/EP2015/057413 WO2015150563A1 (fr) 2014-04-04 2015-04-02 Composés indanone substitués utiles en tant que modulateurs de gpr119 pour le traitement du diabète, de l'obésité, de la dyslipidémie et de troubles associés

Publications (1)

Publication Number Publication Date
SG11201606619UA true SG11201606619UA (en) 2016-09-29

Family

ID=50513188

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606619UA SG11201606619UA (en) 2014-04-04 2015-04-02 Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Country Status (12)

Country Link
US (1) US9896434B2 (fr)
EP (1) EP3126346B1 (fr)
JP (1) JP2017515797A (fr)
KR (1) KR20160132887A (fr)
CN (1) CN106132949A (fr)
AU (1) AU2015239020A1 (fr)
CA (1) CA2942121A1 (fr)
IL (1) IL248118A0 (fr)
MX (1) MX2016013029A (fr)
RU (1) RU2016143092A (fr)
SG (1) SG11201606619UA (fr)
WO (1) WO2015150563A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016013029A (es) 2014-04-04 2017-01-18 Sanofi Sa Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
EP3585775B1 (fr) 2017-02-21 2022-04-06 Sanofi Composés d'azétidine en tant que modulateurs de gpr119 pour le traitement du diabète, de l'obésité, de la dyslipidémie et de troubles associés
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
EP3873877A1 (fr) * 2018-10-31 2021-09-08 Basf Se Procédé de production d'hydroxyméthyl-alcools
CA3142325A1 (fr) * 2019-05-31 2020-12-03 Avolynt Compositions et methodes de traitement d'une maladie metabolique
KR102289381B1 (ko) * 2020-03-17 2021-08-17 주식회사 대웅테라퓨틱스 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471620A1 (fr) * 2001-12-31 2003-07-24 Actelion Pharmaceuticals Ltd Carboxamides de pyrrolidone
EP1638932A1 (fr) 2003-06-18 2006-03-29 Pfizer Products Inc. Nouveaux lactames de piperazinyl-aryloxy et de piperazinyl-heteroaryloxy-n-aryle
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
MX2012013465A (es) * 2010-05-17 2013-12-02 Array Biopharma Inc Lactamas sustituidas con piperidinilo como moduladores de gpr119.
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
RU2013117403A (ru) 2010-09-17 2014-10-27 Эррэй Биофарма Инк. Пиперидинил-замещенные лактамы как модуляторы gpr119
AU2012336157A1 (en) 2011-11-11 2014-05-29 Glaxosmithkline Llc Treatment of blood lipid abnormalities and other conditions
AR092924A1 (es) * 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2016013029A (es) 2014-04-04 2017-01-18 Sanofi Sa Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.

Also Published As

Publication number Publication date
CA2942121A1 (fr) 2015-10-08
JP2017515797A (ja) 2017-06-15
RU2016143092A3 (fr) 2018-10-11
AU2015239020A1 (en) 2016-10-13
US20170029405A1 (en) 2017-02-02
EP3126346A1 (fr) 2017-02-08
CN106132949A (zh) 2016-11-16
US9896434B2 (en) 2018-02-20
EP3126346B1 (fr) 2018-07-11
RU2016143092A (ru) 2018-05-08
WO2015150563A1 (fr) 2015-10-08
MX2016013029A (es) 2017-01-18
KR20160132887A (ko) 2016-11-21
IL248118A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IL248130A0 (en) Isoindolinone compounds as gpr119 regulators in the treatment of diabetes, obesity, dyslipidemia and related diseases
HRP20190369T1 (hr) Spojevi dihidrobenzofurana koji su korisni u liječenju dijabetesa i pretilosti
IL258402B1 (en) Elkrophoresis for the treatment of obesity or diabetes
IL248118A0 (en) Converted inanone compounds as gpr119 regulators for the treatment of diabetes, obesity, dyslipidemia and related diseases
HK1231417A1 (zh) 用於治療眼科疾病和障礙的化合物
IL255185A0 (en) 1-Heteroaryl-indoline-4-carboxamides as gpr52 modulators for treatment or prevention of related disorders
IL248129A0 (en) Transfused Heterocyclics as Gpr119 Regulators for the Treatment of Diabetes, Obesity, Dyslipidemia, and Related Disorders
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
EP3122872A4 (fr) Compositions et méthodes destinées à traiter le diabète de type 1 et type 2 et autres troubles associés
ZA201702403B (en) Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
IL251587A0 (en) Treatment of urological disorders with selective androgen receptor modulators (sarms)
EP3229892A4 (fr) Dispositif non invasif de traitement du reflux gastro- sophagien pathologique
GB201612043D0 (en) Composition for treatment of disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
HK1251449A1 (zh) 用於治療2型糖尿病的交聯聚二烯丙基胺共聚物
IL251392A0 (en) Transformed aromatic compounds and their pharmaceutical preparations for the prevention and treatment of diabetes
EP3313519A4 (fr) Traitement de la myopathie
GB201506228D0 (en) Methods For The Treatment Of Cardivascular Disorders
AU2014901052A0 (en) Device for the treatment of snoring.
GB201602784D0 (en) New treatment of CFTR-related disorders
EP3196190A4 (fr) Dérivés d'indole pour la prévention et/ou le traitement du diabète et de troubles métaboliques associés
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes